Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase 1 9Phase 1/2 7Phase 3 4Phase EARLY_PHASE1 2Phase 4 1

Status

Completed 2Active not recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Gastrointestinal 2Gynecologic 1

Conditions

Melanoma 4Skin Neoplasms 3Skin Diseases 2Neoplasm Metastasis 2Neoplasms 1

Interventions

Dacarbazine 27Nivolumab 26pembrolizumab 22Ipilimumab 203-ingenyl angelate 11Interferon-alpha 10Imiquimod 10Temozolomide 9trametinib 8Vemurafenib 8Photochemotherapy 8Aminolevulinic Acid 8methyl 5-aminolevulinate 7dabrafenib 7cemiplimab 7aldesleukin 7Introns 7Surgical Procedures, Operative 6Radiotherapy 6Interferon alpha-2 6Fluorouracil 6Paclitaxel 5Melphalan 5Interleukin-2 5Cisplatin 5Chemotherapy, Adjuvant 5talimogene laherparepvec 4binimetinib 4Specimen Handling 4Opdualag 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × binimetinib × Dermatologic × Clear all
NCT04657991 2026-04-07

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Pfizer

Phase 3 Active not recruiting
257 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT01909453 2026-02-27

COLUMBUS

Pfizer

Phase 3 Completed
921 enrolled 48 charts 1 FDA
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT05270044 2023-11-22

COLUMBUS-AD

Pierre Fabre Medicament

Phase 3 Active not recruiting
815 enrolled
Dermatologic

Melanoma

NCT01763164 2021-03-22

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Pfizer

Phase 3 Completed
402 enrolled 21 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Diseases, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡